News
-
-
-
-
-
PRESS RELEASE
Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Galimedix Therapeutics presents compelling Phase 1 study results at CTAD 2025, demonstrating excellent safety and pharmacokinetics of GAL-101, planning Phase 2 study in Alzheimer's disease -
-
-
-
PRESS RELEASE
SCHOTT Pharma’s preliminary results for fiscal year 2025; outlook for FY 2026 and update of mid-term guidance
SCHOTT Pharma's preliminary results for fiscal year 2025 show revenue growth and increased EBITDA margin. Outlook for FY 2026 includes moderate revenue growth and mid-term guidance updates towards 30% EBITDA margin by 2029 -